Given the limited number of studies included as well as the significant heterogeneity, more randomized and large-scale clinical trials, carefully controlled for potential confounding factors, are needed to confirm this association between resistin levels and obesity-related cancer risk in the future. The gene discussed is RETN; the disease is obesity due to melanocortin 4 receptor deficiency.